NICE consults on potential cancer indicators for the QOF

The National Institute for Health and Clinical Excellence has today launched a consultation on potential new indicators for the Quality and Outcomes Framework (QOF).  The consultation for the potential 20 new indicators for the 2013/14 QOF is open for a four week period which will close at 5.00pm on Monday 6th February 2012.

The consultation document is available here, and the relevant cancer indicators proposed are:

  • The percentage of patients with cancer diagnosed within the preceding 18 months who have a review recorded as occurring within 3 months of the practice receiving confirmation of the diagnosis
  • The percentage of patients with recurrent or distant metastatic cancer diagnosed within the preceding 18 months who have a review recorded as occurring within 3 months of the practice receiving confirmation of the diagnosis

The comments proforma is available here.

Page published: Mon 9 January 2012

It is supported by 12 companies:

  • Amgen
  • Astra Zeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • GE Healthcare
  • GSK
  • Lilly
  • Novartis
  • Pfizer
  • Roche
  • Sanofi Aventis